Kenya Murata

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Michael G. Hanna, Umesh A. Badrising, Olivier Benvéniste et al. · The Lancet Neurology · 2019 · 128 citations · Full text

Autoimmune Disease, Immunology, Placebo-controlled Phase 2B +4

Expression of the Costimulatory Molecule BB-1, the Ligands CTLA-4 and CD28, and their mRNA in Inflammatory Myopathies

Kenya Murata, Marinos C. Dalakas · American Journal Of Pathology · 1999 · 112 citations · Full text

Inflammation, Autoimmune Disease, Ligands Ctla-4 +10

Statins and Myotoxic Effects Associated With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies

Yurika Watanabe, Shigeaki Suzuki, Hiroaki Nishimura et al. · Medicine · 2015 · 87 citations · Full text

Rheumatology, Autoimmune Disease, Medicine +15

Clinical Features of Autoimmune Autonomic Ganglionopathy and the Detection of Subunit-Specific Autoantibodies to the Ganglionic Acetylcholine Receptor in Japanese Patients

Shunya Nakane, Osamu Higuchi, Michiaki Koga et al. · PLoS ONE · 2015 · 83 citations · Full text

Immunodeficiencies, Immunology, Clinical Features +19

Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy

Kenya Murata · Brain · 2000 · 71 citations · Full text